Alector stock rises after pricing equity offering (ALEC:NASDAQ)

Alector (ALEC) stock rose 11.2% in pre-market trading after pricing a $75 million common stock offering at $2.05 per share, a 7.3% premium. The offering attracted institutional investors, and H.C. Wainwright raised its price target to $8. The company plans to use proceeds for R&D and potential strategic transactions.

Alector's stock rose 13% premarket after announcing a $75M equity offering at $2.05/share, a 7.3% premium over the prior close. Proceeds will fund R&D, working capital, and potential acquisitions. The offering is expected to close by October 19, 2026, with participation from new and existing investors.

Alector, Inc. (ALEC) announced a 36.6M-share offering priced at $2.05, raising ~$75.03M. The offering is a 7.3% premium to its Oct. 15 closing price, with proceeds earmarked for neurodegeneration R&D. The deal is expected to close Oct. 19, pending customary conditions.

Alector, Inc. (ALEC) announced a $75M common stock offering, selling 36.6M shares. Proceeds will fund research, development, and potential acquisitions. Morgan Stanley and BTIG are lead managers. The offering is under a previously filed SEC registration statement.

Alector (ALEC) licensed AL-050 to Genentech, receiving $100M upfront and up to $1.17B more. Genentech gains worldwide rights. Retail sentiment on Stocktwits was bullish for VTRS, PCRX, and ALEC, neutral for GEHC and BHVN. Year-to-date gains: VTRS +42%, PCRX +40%, ALEC +33%, BHVN +7%, GEHC -20%.

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.